Research highlights the use of multimodal machine learning to identify non-small cell lung cancer patients predicted to derive the most benefit from combination immunotherapy.
Research presented will include the applications of new diagnostic tools and machine learning multimodal signatures in clinical trials.
The global collective intelligence network aims to accelerate precision oncology research and care.
The companies commit to bring cutting-edge liquid biopsy testing to 20 institutions globally over the next 12 months
The Society brings together over 87 academic and industry leaders in liquid biopsy.
The companies share how their collaboration enables clinical trial enrollment for a novel cancer therapy for oncogene amplified cancers in development by Boundless Bio.
New generation of SOPHiA DDM™ integrates latest advancements in data processing and technology to deliver elevated experience and capabilities to customers.
BOSTON, United States and ROLLE, Switzerland, August 28, 2024 — SOPHiA GENETICS, a cloud-native...
Regulatory milestone validates the SOPHiA DDM™ Platform as diagnostic tool in select markets.
Strength in U.S. Growth Offset by Challenges in BioPharma and EMEA; Strong Cost Management Buffers Loss
This week is marking one year from the official launch of the SOPHiA DDM TM Homologous Recombination Deficiency (HRD) Solution, accelerating and empowering our customers’ clinical cancer research decisions with cost-effective, accurate and fast in-house results.
Last week we attended the European Society for Medical Oncology (ESMO) Congress 2022, gathering the world’s leading oncologists. Read our summary of three presentations illustrating cancer therapy development.
